S-Nitrosothiols signal hypoxia-mimetic vascular pathology

Lisa A. Palmer, Allan Doctor, Preeti Chhabra, Mary Lynn Sheram, Victor E. Laubach, Molly Z. Karlinsey, Michael S. Forbes, Timothy Macdonald, Benjamin Gaston

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

NO transfer reactions between protein and peptide cysteines have been proposed to represent regulated signaling processes. We used the pharmaceutical antioxidant N-acetylcysteine (NAC) as a bait reactant to measure NO transfer reactions in blood and to study the vascular effects of these reactions in vivo. NAC was converted to S-nitroso-N-acetylcysteine (SNOAC), decreasing erythrocytic S-nitrosothiol content, both during wholeblood deoxygenation ex vivo and during a 3-week protocol in which mice received high-dose NAC in vivo. Strikingly, the NAC-treated mice developed pulmonary arterial hypertension (PAH) that mimicked the effects of chronic hypoxia. Moreover, systemic SNOAC administration recapitulated effects of both NAC and hypoxia. eNOS-deficient mice were protected from the effects of NAC but not SNOAC, suggesting that conversion of NAC to SNOAC was necessary for the development of PAH. These data reveal an unanticipated adverse effect of chronic NAC administration and introduce a new animal model of PAH. Moreover, evidence that conversion of NAC to SNOAC during blood deoxygenation is necessary for the development of PAH in this model challenges conventional views of oxygen sensing and of NO signaling.

Original languageEnglish (US)
Pages (from-to)2592-2601
Number of pages10
JournalJournal of Clinical Investigation
Volume117
Issue number9
DOIs
StatePublished - Sep 4 2007

Fingerprint

S-Nitrosothiols
Acetylcysteine
Blood Vessels
Pathology
Pulmonary Hypertension
Hypoxia
Cysteine
Animal Models
Antioxidants
S-nitroso-N-acetylcysteine
Oxygen

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Palmer, L. A., Doctor, A., Chhabra, P., Sheram, M. L., Laubach, V. E., Karlinsey, M. Z., ... Gaston, B. (2007). S-Nitrosothiols signal hypoxia-mimetic vascular pathology. Journal of Clinical Investigation, 117(9), 2592-2601. https://doi.org/10.1172/JCI29444

S-Nitrosothiols signal hypoxia-mimetic vascular pathology. / Palmer, Lisa A.; Doctor, Allan; Chhabra, Preeti; Sheram, Mary Lynn; Laubach, Victor E.; Karlinsey, Molly Z.; Forbes, Michael S.; Macdonald, Timothy; Gaston, Benjamin.

In: Journal of Clinical Investigation, Vol. 117, No. 9, 04.09.2007, p. 2592-2601.

Research output: Contribution to journalArticle

Palmer, LA, Doctor, A, Chhabra, P, Sheram, ML, Laubach, VE, Karlinsey, MZ, Forbes, MS, Macdonald, T & Gaston, B 2007, 'S-Nitrosothiols signal hypoxia-mimetic vascular pathology', Journal of Clinical Investigation, vol. 117, no. 9, pp. 2592-2601. https://doi.org/10.1172/JCI29444
Palmer LA, Doctor A, Chhabra P, Sheram ML, Laubach VE, Karlinsey MZ et al. S-Nitrosothiols signal hypoxia-mimetic vascular pathology. Journal of Clinical Investigation. 2007 Sep 4;117(9):2592-2601. https://doi.org/10.1172/JCI29444
Palmer, Lisa A. ; Doctor, Allan ; Chhabra, Preeti ; Sheram, Mary Lynn ; Laubach, Victor E. ; Karlinsey, Molly Z. ; Forbes, Michael S. ; Macdonald, Timothy ; Gaston, Benjamin. / S-Nitrosothiols signal hypoxia-mimetic vascular pathology. In: Journal of Clinical Investigation. 2007 ; Vol. 117, No. 9. pp. 2592-2601.
@article{c7dbbc6c93b54772815c793843060182,
title = "S-Nitrosothiols signal hypoxia-mimetic vascular pathology",
abstract = "NO transfer reactions between protein and peptide cysteines have been proposed to represent regulated signaling processes. We used the pharmaceutical antioxidant N-acetylcysteine (NAC) as a bait reactant to measure NO transfer reactions in blood and to study the vascular effects of these reactions in vivo. NAC was converted to S-nitroso-N-acetylcysteine (SNOAC), decreasing erythrocytic S-nitrosothiol content, both during wholeblood deoxygenation ex vivo and during a 3-week protocol in which mice received high-dose NAC in vivo. Strikingly, the NAC-treated mice developed pulmonary arterial hypertension (PAH) that mimicked the effects of chronic hypoxia. Moreover, systemic SNOAC administration recapitulated effects of both NAC and hypoxia. eNOS-deficient mice were protected from the effects of NAC but not SNOAC, suggesting that conversion of NAC to SNOAC was necessary for the development of PAH. These data reveal an unanticipated adverse effect of chronic NAC administration and introduce a new animal model of PAH. Moreover, evidence that conversion of NAC to SNOAC during blood deoxygenation is necessary for the development of PAH in this model challenges conventional views of oxygen sensing and of NO signaling.",
author = "Palmer, {Lisa A.} and Allan Doctor and Preeti Chhabra and Sheram, {Mary Lynn} and Laubach, {Victor E.} and Karlinsey, {Molly Z.} and Forbes, {Michael S.} and Timothy Macdonald and Benjamin Gaston",
year = "2007",
month = "9",
day = "4",
doi = "10.1172/JCI29444",
language = "English (US)",
volume = "117",
pages = "2592--2601",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "9",

}

TY - JOUR

T1 - S-Nitrosothiols signal hypoxia-mimetic vascular pathology

AU - Palmer, Lisa A.

AU - Doctor, Allan

AU - Chhabra, Preeti

AU - Sheram, Mary Lynn

AU - Laubach, Victor E.

AU - Karlinsey, Molly Z.

AU - Forbes, Michael S.

AU - Macdonald, Timothy

AU - Gaston, Benjamin

PY - 2007/9/4

Y1 - 2007/9/4

N2 - NO transfer reactions between protein and peptide cysteines have been proposed to represent regulated signaling processes. We used the pharmaceutical antioxidant N-acetylcysteine (NAC) as a bait reactant to measure NO transfer reactions in blood and to study the vascular effects of these reactions in vivo. NAC was converted to S-nitroso-N-acetylcysteine (SNOAC), decreasing erythrocytic S-nitrosothiol content, both during wholeblood deoxygenation ex vivo and during a 3-week protocol in which mice received high-dose NAC in vivo. Strikingly, the NAC-treated mice developed pulmonary arterial hypertension (PAH) that mimicked the effects of chronic hypoxia. Moreover, systemic SNOAC administration recapitulated effects of both NAC and hypoxia. eNOS-deficient mice were protected from the effects of NAC but not SNOAC, suggesting that conversion of NAC to SNOAC was necessary for the development of PAH. These data reveal an unanticipated adverse effect of chronic NAC administration and introduce a new animal model of PAH. Moreover, evidence that conversion of NAC to SNOAC during blood deoxygenation is necessary for the development of PAH in this model challenges conventional views of oxygen sensing and of NO signaling.

AB - NO transfer reactions between protein and peptide cysteines have been proposed to represent regulated signaling processes. We used the pharmaceutical antioxidant N-acetylcysteine (NAC) as a bait reactant to measure NO transfer reactions in blood and to study the vascular effects of these reactions in vivo. NAC was converted to S-nitroso-N-acetylcysteine (SNOAC), decreasing erythrocytic S-nitrosothiol content, both during wholeblood deoxygenation ex vivo and during a 3-week protocol in which mice received high-dose NAC in vivo. Strikingly, the NAC-treated mice developed pulmonary arterial hypertension (PAH) that mimicked the effects of chronic hypoxia. Moreover, systemic SNOAC administration recapitulated effects of both NAC and hypoxia. eNOS-deficient mice were protected from the effects of NAC but not SNOAC, suggesting that conversion of NAC to SNOAC was necessary for the development of PAH. These data reveal an unanticipated adverse effect of chronic NAC administration and introduce a new animal model of PAH. Moreover, evidence that conversion of NAC to SNOAC during blood deoxygenation is necessary for the development of PAH in this model challenges conventional views of oxygen sensing and of NO signaling.

UR - http://www.scopus.com/inward/record.url?scp=34848881907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848881907&partnerID=8YFLogxK

U2 - 10.1172/JCI29444

DO - 10.1172/JCI29444

M3 - Article

C2 - 17786245

AN - SCOPUS:34848881907

VL - 117

SP - 2592

EP - 2601

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 9

ER -